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We assessed Escherichia coli ST131 and its H30 and H30-Rx subclones for virulence genes, antimicrobial resistance, and
extended-spectrum beta-lactamase (ESBL) type. Although both subclones were associated with ESBL production, H30-Rx iso-
lates had higher resistance scores and were associated specifically with CTX-M-15. Three virulence genes (iha, sat, and iutA) were
more prevalent among H30 than non-H30 ST131 isolates. Thus, the H30 and H30-Rx subclones are more antimicrobial resistant
and have virulence profiles that are distinct from those of non-H30 ST131 isolates.
The H30 and H30-Rx subclones of Escherichia coli sequencetype 131 (ST131) have expanded more extensively than other
ST131 variants, for as-yet-unexplained reasons. The H30 sub-
clone, so named because it contains allele 30 of fimH (type 1 fim-
brial adhesin gene), comprises almost all current fluoroquin-
olone-resistant ST131 isolates (1). Within the H30 subclone, the
H30-Rx subset often carries blaCTX-M-15 and may constitute its
main repository within ST131 (2). Here we determined the prev-
alence of ST131 and its H30 and H30-Rx subclones among isolates
from a case-control study of infections caused by extended-spec-
trum--lactamase (ESBL)-producing E. coli strains (3) and com-
pared these groups for virulence genotypes, antimicrobial resis-
tance, and ESBL type.
A total of 267 (100 ESBL-positive and 167 ESBL-negative) E.
coli isolates were collected prospectively between 2007 and 2010
for a case-control study, as described in detail elsewhere (3), with
approval by the NorthShore and VA Medical Center institutional
review boards. Fifteen health care-associated isolates, collected
during the prospective study 2 days after hospital admission,
were excluded from the study reported in reference 3 but were
evaluated here. Established PCR-based methods were used to de-
fine E. coli phylogenetic group (A, B1, B2, and D) (4), ST131 and
its H30 subclone (1, 2, 5), major CTX-M groups (6), the presence
of blaCTX-M-15 (7), and extended virulence genotypes (8–10). The
H30-Rx subclone was identified by PCR detection of a specific
single-nucleotide polymorphism (SNP) (G723A) within the al-
lantoin-encoding gene, ybbW (2). Primers APfor63 (5=-GGTTGC
GGTCTGGGCA-3=) and APrev66 (5=-CAATATCCAGCACGTT
CCAGGTG-3=), with a cycling routine of 95°C for 8 min, 31 cycles
of 94°C for 20 s and 72°C for 40 s, and a final extension at 72°C (for
5=), yielded a 194-bp amplicon. The resistance score was the total
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FIG 1 Resistance phenotypes and ESBL types among 71 ST131 isolates. (A) All
71 ST131 isolates, stratified by H30 subclone status. (B) The 62 H30 subclone
isolates, stratified by H30-Rx status. ESBL, extended-spectrum -lactamase;
FQ-R, fluoroquinolone resistant. Prevalence values reflect percentages of iso-
lates within each indicated subgroup.
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number of agents (among 7) to which an isolate was resistant. The
virulence score was as described previously (11). Fisher’s exact test
and the Mann-Whitney U test were used for comparisons involv-
ing dichotomous and continuous variables, respectively; a P value
of 0.05 was considered statistically significant. Principal coordi-
nate analysis (PCoA) was used to reduce the dimensionality of the
molecular data set for simplified comparisons (12).
The 100 ESBL-positive (49% ST131) and 167 ESBL-negative
(13% ST131; P  0.001) study isolates were predominantly from
urine (92%) and community-associated infections (95%). The
most prevalent ESBL type overall was CTX-M (84%), predomi-
nantly CTX-M-15 (73%), followed by group 9 CTX-M variants
(11%). CTX-M-15 was not significantly associated with ST131
(data not shown).
Among the 49 ESBL-positive ST131 isolates, 48 (98%) repre-
sented the H30 subclone, and 44 (92%) of these represented the
H30-Rx subclone. In contrast, among the 22 ESBL-negative
ST131 isolates, only 14 (64%) represented the H30 subclone (P 
0.001), and only 3 (14%) of these represented the H30-Rx sub-
clone (P  0.001).
H30 ST131 subclone isolates were overwhelmingly fluoro-
quinolone resistant (98%) and ESBL positive (77%), whereas few
non-H30 ST131 isolates were (Fig. 1A). Among H30 isolates, 94%
of H30-Rx isolates, but only 27% of other H30 isolates, were ESBL
positive (Fig. 1B). Within ST131, ESBL subtype varied signifi-
cantly by subclone, with CTX-M-15 being associated with H30-Rx
and CTX-M-9 being associated with other H30 isolates (Fig. 1A).
Antimicrobial resistance also varied by subclone, with H30
subclone isolates having a higher prevalence of beta-lactam and
ciprofloxacin resistance (Table 1) and higher resistance scores
(median, 5 versus 3; P  0.001). Similarly, among H30 isolates,
H30-Rx isolates had a higher prevalence of resistance to cephalo-
sporins (Table 1) and higher resistance scores (median, 6 versus 3;
P  0.01).
Virulence scores were significantly lower overall among ESBL-
positive than ESBL-negative isolates (median, 9 versus 11; P 
0.001) and among non-ST131 ESBL-positive than non-ST131
ESBL-negative isolates (median, 6 versus 12; P  0.001). In con-
trast, ST131 isolates had similar virulence scores (median, 10)
regardless of ESBL status. Among ESBL-negative isolates, viru-
lence scores were slightly lower among ST131 than non-ST131
isolates (median, 10 versus 12; P  0.03). In contrast, among
ESBL-positive isolates, virulence scores were much greater among
ST131 than non-ST131 isolates (median, 10 versus 6; P  0.001).
Within ST131, several virulence factor (VF) genes were sub-
clone specific, with iha, sat, and iutA occurring predominantly
among H30 isolates but iroN, K1, and ibeA occurring predomi-
nantly among non-H30 isolates (Table 2). In contrast, among H30
isolates, only kpsMII and K5 differed in prevalence between
TABLE 1 Antimicrobial resistance by ST131 subclone among 71 Escherichia coli ST131 isolates
Antimicrobial agent
Within ST131 Within H30 ST131 subclone
No. (%) of resistant strains
Pa
No. (%) of resistant strains
PaH30 (n  62) Non-H30 (n  9) H30-Rx (n  47) Other H30 (n  15)
Ampicillin 61 (98) 7 (78) 0.04 46 (98) 15 (100)
Cefazolin 48 (77) 1 (11) 0.001 43 (91) 5 (33) 0.001
Ceftriaxone 46 (74) 1 (11) 0.001 42 (89) 4 (27) 0.001
Ceftazidime 44 (71) 1 (11) 0.001 40 (85) 4 (27) 0.001
Gentamicin 23 (37) 5 (56) 15 (32) 8 (53)
Ciprofloxacin 61 (98) 2 (22) 0.001 46 (98) 15 (100)
TMP-SMZb 31 (50) 6 (67) 21 (45) 10 (67)
a Determined by Fisher’s exact test. Values are shown where P is 0.05; for all other comparisons, P was 0.10.
b TMP-SMZ, trimethoprim-sulfamethoxazole.
TABLE 2 Virulence gene distribution by ST131 subclone among 71 ST131 Escherichia coli isolates
Functional category Genea
Within ST131 Within H30 ST131 subclone
No. (%) of strains carrying gene
Pb
No. (%) of strains carrying gene
PbH30 (n  62) Non-H30 (n  9) H30-Rx (n  47) Other H30 (n  15)
Adhesin iha 60 (97) 5 (56) 0.002 45 (96) 15 (100)
Toxin sat 61 (98) 3 (33) 0.001 46 (98) 15 (100)
Siderophores iroN 1 (2) 2 (22) 0.04 1 (2) 0
iutA 56 (90) 5 (56) 0.02 42 (89) 14 (93)
Protectins kpsMII 53 (85) 8 (89) 44 (94) 9 (60) 0.004
K1 2 (3) 3 (33) 0.01 1 (2) 1 (7)
K5 17 (27) 1 (11) 9 (19) 8 (53) 0.02
Other ibeA 0 6 (67) 0.001 0 0
a Virulence genes listed are those that yielded P values of 0.05 in at least one comparison.
b Determined by Fisher’s exact test. Values are shown where P is 0.05; for all other comparisons, the differences were not significant.
Banerjee et al.
6386 aac.asm.org Antimicrobial Agents and Chemotherapy
H30-Rx and non-H30-Rx isolates (Table 2). Virulence scores were
similar across the ST131 subclones (median for each, 10).
According to PCoA, ST131 isolates had distinctive virulence
profiles relative to non-ST131 isolates, and each subclone group
within ST131 (H30-Rx, other H30, and non-H30) had a charac-
teristic profile (Fig. 2). Among the ST131 isolates, H30 (non-H30-
Rx) profiles were most homogeneous, whereas non-H30 profiles
were most diverse and overlapped most with those of non-ST131
isolates (Fig. 2).
Here we determined the prevalence of ST131 and its H30 and
H30-Rx subclones and explored their associations with resistance
phenotypes, ESBL types, and virulence profiles, among prospec-
tively collected E. coli clinical isolates from the Chicago area (2007
to 2010). We confirmed the well-established association between
ST131 and ESBL production (13–15), and found that the recently
identified H30 ST131 subclone (1, 2, 5, 16) has expanded in the
study region more than non-H30 ST131 subclones. Furthermore,
we found that within ST131, CTX-M-15 was confined almost ex-
clusively to the H30-Rx subset.
Our findings confirm, in a geographically distinct popula-
tion, recent whole-genome-based evidence that within ST131,
blaCTX-M-15 is transmitted mainly vertically within the H30-Rx
lineage, after what was probably a single ancestral acquisition
event (2). Our findings also uniquely document a continuum of
increasing antimicrobial resistance within ST131, from the non-
H30 (most susceptible) isolates to the H30-Rx isolates (most re-
sistant).
Furthermore, we document that, among ESBL-positive iso-
lates, ST131 isolates—mostly representing the H30-Rx sub-
clone— have higher virulence scores than non-ST131 isolates, im-
plying greater virulence potential and thereby possibly explaining
their high prevalence. We also identified three VF genes (iha, sat,
and iutA) that are more prevalent among H30 than non-H30
ST131 isolates. The mechanisms whereby specific accessory traits
may facilitate the epidemiologic success of ST131 and its principal
subclones deserve further study.
Study limitations include the fact that most isolates were from
urine and community onset infections and hence may not be rep-
resentative of isolates causing invasive infections. We also lacked
clinical data, so we could not correlate bacterial traits with infec-
tion severity. Study strengths include the fact that that we evalu-
ated a large number of ESBL-positive and ESBL-negative clinical
isolates and used novel SNP-based PCR assays to identify the re-
cently recognized H30 and H30-Rx subclones within ST131.
In conclusion, among ESBL-positive E. coli strains in the study
region, the H30 ST131 subclone now accounts for almost half of
ESBL-positive E. coli strains causing infections, with CTX-M-15,
the most common ESBL type, being carried almost exclusively by
the H30-Rx subset within H30. Elucidation of the molecular and
ecologic basis for the epidemiologic success of ST131, especially its
H30 and H30-Rx components, could inform the development of
interventions against further spread of these highly antimicrobial-
resistant lineages.
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